文献速递白血病造血干细胞移植与细胞治疗

即时制备新鲜CAR-T细胞治疗复发/难治或极高危首次复发的儿童或青年B细胞前体急性淋巴细胞白血病

Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.
PubMed 文献 · Blood Adv · 2025-01-01

这项1/2期试验采用CliniMACS Prodigy 12天工艺即时制备新鲜自体CD19 CAR-T细胞,治疗19例B细胞前体急性淋巴细胞白血病患者(13例为极高危首次复发)。1期未观察到剂量限制性毒性,所有患者均达骨髓完全缓解且微小残留病阴性;全队列3年无事件生存率68%、总生存率83%。

要点

  • 即时制备的CD19 CAR-T细胞在19例B-ALL患者中均成功生产,1期未见剂量限制性毒性。
  • 所有患者达骨髓完全缓解且微小残留病阴性;13例(68%)维持完全缓解,其中7例接受造血干细胞移植巩固。
  • 全队列3年无事件生存率68%、总生存率83%;3.0×10^6 CAR+ T细胞/kg组除1例外均维持完全缓解。

核心结论

  • 即时制备的自体抗CD19 CAR-T细胞可成功治疗B细胞前体急性淋巴细胞白血病患者,包括极高危首次复发者。

研究设计与样本

  • 1/2期试验(NCT04787263),采用第二代(4.1BB)CD19 CAR-T细胞,经CliniMACS Prodigy 12天工艺从新鲜单采血制备并新鲜输注。
  • 纳入19例B细胞前体急性淋巴细胞白血病患者,其中13例(68%)为极高危首次复发;1期测试1.0、2.0、3.0×10^6 CAR+ T细胞/kg三个剂量水平。

主要发现

  • 设计剂量均成功生产,1期未观察到剂量限制性毒性。
  • 1~2级细胞因子释放综合征见于13例(68%)患者;1~2级免疫效应细胞相关神经毒性综合征见于2例并自行缓解。
  • 所有患者均达骨髓完全缓解且微小残留病阴性;8例(42%)接受造血干细胞移植巩固。
  • 全队列中13/19例(68%)维持完全缓解,其中7例接受过造血干细胞移植;3.0×10^6 CAR+ T细胞/kg组除1例外均维持完全缓解。
  • 全队列3年无事件生存率为68%,总生存率为83%。

关键数值与推荐

  • 1期剂量水平:1.0、2.0、3.0×10^6 CAR+ T细胞/kg。
  • 完全缓解维持率:13/19例(68%),其中7例接受造血干细胞移植。
  • 3年无事件生存率68%,总生存率83%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The point-of-care, automated manufacturing of chimeric antigen receptor (CAR) T cells can reduce the waiting window and increase the therapy accessibility to patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) as compared with commercially available drug products (DPs). We conducted a phase 1/2 trial (NCT04787263) on the use of second-generation (4.1BB), CD19-CAR T cells, for the treatment of patients with BCP-ALL with either first relapse and very-high-risk (VHR) characteristics or second/subsequent relapse and rapidly progressing disease. CAR T cells were manufactured with a 12-day process using CliniMACS Prodigy, from a fresh apheresis and infused fresh. Three dose levels were tested in the phase 1: 1.0, 2.0, and 3.0×106 CAR+ T cells/kg. Nineteen patients were enrolled, 13 (68%) in first VHR relapse. The designed dose was always successfully produced. No dose-limiting toxicities were observed in the phase 1. Grade 1 to 2 cytokine release syndrome was observed in 13 (68%) patients. Grade 1 to 2 immune effector cell-associated neurotoxicity syndrome occurred in 2 patients and resolved spontaneously. All patients achieved bone marrow complete remission (CR) with negative minimal residual disease. Eight patients (42%) received hematopoietic stem cell transplantation (HSCT) consolidation. Overall, CR was maintained in 13 of 19 patients (68%), 7 of whom having received HSCT. Importantly, all but 1 patient treated with 3.0×106 CAR+ T cells/kg maintained CR. The 3-year event-free survival and overall survival of the whole cohort are 68% and 83%, respectively. Our data suggest that the point-of-care manufacturing of autologous, anti-CD19 CAR T cells can successfully treat patients with BCP-ALL including those with first relapse and VHR characteristics.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Del Bufalo F, Becilli M, Rosignoli C, et al. Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse. Blood Adv. 2025. PMID: 40558311. doi:10.1182/bloodadvances.2025016181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。